Flare Capital Partners
Flare Capital Partners is a Boston-based healthtech venture capital firm managing ~$1B AUM across 83 portfolio companies and 22 exits. It invests Seed-to-Series B alongside a pre-seed Scholar Ventures vehicle, supported by a 35-member Industry Advisory Board and 14-member AI Advisory Council driving ~$1B in portfolio revenue.
- Company typePrivate
- Founded2011
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Flare Capital Partners does
Flare Capital Partners is a Boston-based venture capital firm specializing exclusively in healthcare technology, managing approximately $1 billion in assets under management across its funds. Founded in 2013 (per the firm's homepage) with operations traceable to 2011, the firm has invested over $450 million in 83 portfolio companies and achieved 22 exits including one IPO (Bright Health Group) and multiple acquisitions (Aetion, Curisium). It invests in founders from Seed through Series B with typical checks of $5M–$30M and 10%–20% target ownership, alongside a separate Flare Scholar Ventures vehicle that deploys approximately $100,000 of pre-seed capital into companies sourced from a 509-person Flare Scholars talent network.
The firm operates a three-pillar model spanning sourcing, funding, and go-to-market acceleration. The Core Investments pillar holds Seed-to-Series B positions in companies such as Qualified Health, Suki, SmarterDx, Cohere Health, Oshi Health, knownwell, Keebler Health, Daffodil Health, and Atlas Oncology Partners. Flare Scholar Ventures is a proprietary pre-seed deal engine, and the Flare Scholars Program is an annual professional development community of 509 emerging leaders. Wrapping these pillars are two proprietary network products: a 35-member Industry Advisory Board whose member companies represent approximately $1.2 trillion in revenue, ~15% of U.S. healthcare spend, 68.5 million insured lives, and 35,210 hospital beds; and a 14-member AI Advisory Council including senior leaders from Microsoft, AWS, Amgen, CVS Health, GuideWell, Banner Health, and MedStar Health. The Strategic Engagement Model operationalizes these networks, contributing approximately $1 billion in direct revenue to portfolio companies through buyer introductions.
The business model is classic venture capital: recurring management fees on committed capital under a fund-of-funds structure, supplemented by realized carried interest on exits. Distribution is purely domestic U.S. and is relationship-driven rather than transactional, leveraging IAB referrals, AI Council pilots, and Flare Scholars deal flow rather than any public product. The firm is privately held with no disclosed parent company; Michael Greeley serves as Co-Founder and General Partner, Adam Bruce as Partner, CFO and COO, and a team of approximately 24 investment professionals and executive partners (including former CDC Director Dr. Rochelle Walensky and former Partners HealthCare CEO Gary Gottlieb MD).
Flare Capital Partners firmographics
Firmographics- Name
- Flare Capital Partners
- Legal name
- Flare Capital Partners
- Website
- https://flarecapital.com
- Company type
- Private
- Founded year
- 2011
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Flare Capital Partners is a Boston-based healthtech venture capital firm managing ~$1B AUM across 83 portfolio companies and 22 exits. It invests Seed-to-Series B alongside a pre-seed Scholar Ventures vehicle, supported by a 35-member Industry Advisory Board and 14-member AI Advisory Council driving ~$1B in portfolio revenue.
- Ownership category
- akta.pro rank
Flare Capital Partners industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- Investment Banking and Securities Intermediation (523150), Portfolio Management and Investment Advice (523940)
- SIC
- Security Brokers, Dealers & Flotation Companies (6211), Investment Advice (6282)
- akta.pro primary industry
- Early-Stage Venture Capital (Series A/B) (FSANAAAB)
- akta.pro secondary industries
- Late-Stage Venture Capital (Series C+) (FSANAAAC), Accelerators & Incubators (Investor-Operated) (FSANAAAM)
Keywords
Where Flare Capital Partners is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Markets served
Flare Capital Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Fund Management (implied): Manages approximately $1B in assets under management across the firm's healthtech-focused venture funds, generating recurring management fees on committed capital.
- Portfolio Exits / Carried Interest (implied): Realizes returns through 22 portfolio company exits to date (with Aetion and Curisium among acquired companies; Bright Health Group among IPO'd companies; Iora Health, Docent, Valence Health among exited). Returns are recycled through 10%-20% target ownership stakes in 83 portfolio companies.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Core Investments: Seed to Series B, $5M-$30M total investment per company, 10%-20% target ownership |
| Other | Pay-as-you-go | Flare Scholar Ventures: ~$100K pre-seed ticket to companies founded, advised, or supported by Flare Scholars network |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels11 records
Flare Capital Partners product offering
Product offeringCore offering
Flare Capital Partners provides venture capital investment, network-driven portfolio acceleration, and talent-community engagement exclusively to U.S. healthcare technology founders. Its primary offering is direct equity investment of $5 million to $30 million per company across Seed to Series B rounds with 10%–20% target ownership, complemented by a ~$100K pre-seed vehicle (Flare Scholar Ventures), a 35-member Industry Advisory Board opening enterprise buyer relationships, a 14-member AI Advisory Council supporting AI deployments, and a 509-member Flare Scholars talent community that sources both deals and operating talent.
Product overview
Flare Capital Partners is a healthtech-focused venture capital firm, not a SaaS product company; its offering is a multi-vehicle investment platform built around three coordinated pillars. The Core Investments pillar partners with founders from Seed through Series B (typical checks $5M–$30M, target ownership 10%–20%), and houses the majority of named portfolio products such as Qualified Health, Suki, SmarterDx, Cohere Health, Oshi Health, knownwell, Peer AI, Cascala Health, Isaac Health, Keebler Health, Atlas Oncology Partners, Daffodil Health, Photon Health, Layer Health, and Lynx. Flare Scholar Ventures is a proprietary pre-seed deal engine deploying approximately $100K into companies sourced from the Flare Scholars Program, a 509-person annual talent and mentorship community. Wrapping these pillars are two network products that operationalize the firm’s strategic engagement: a 35-member Industry Advisory Board representing ~15% of U.S. healthcare spend, and a 14-member AI Advisory Council that supports portfolio AI deployments. Together, these pillars form a single connected healthtech investment platform spanning sourcing (Scholars), funding (Scholar Ventures + Core), and go-to-market acceleration (IAB + AI Council).
Differentiator
Problem solved
Functional benefit
Brands
- Flare Scholar Ventures: Proprietary pre-seed deal engine deploying ~$100K of capital to back companies founded, advised, or supported by the Flare Scholars network.
- Flare Scholars
Products and services
- Core Investments (Seed-to-Series B venture capital) The firm's primary investment offering: direct equity capital of $5M–$30M per company in U.S. healthtech founders at Seed through Series B, targeting 10%–20% ownership, with multi-cycle support and access to the Strategic Engagement Model, Industry Advisory Board, and AI Advisory Council. For healthtech founders seeking institutional venture capital.
- Flare Scholar Ventures (pre-seed investment vehicle) A proprietary pre-seed investment engine that deploys approximately $100K of equity capital into companies founded, advised, or supported by members of the 509-strong Flare Scholars talent network. For very early-stage healthtech founders affiliated with the Flare Scholars community.
- Industry Advisory Board engagement (buyer introductions) A 35-member advisory board of senior healthcare executives from organizations representing ~$1.2T in revenue and ~15% of all U.S. healthcare spend, providing portfolio founders with frontline market intelligence, buyer introductions, and partnership pathways. Bundled with Core Investments for portfolio companies.
- AI Advisory Council engagement A 14-member advisory council of senior AI and healthcare leaders from organizations including Microsoft, AWS, Amgen, CVS Health, GuideWell, Banner Health, and Children's Hospital, providing structured AI evaluation, market benchmarking, and pilot pathways for AI-focused portfolio companies. Bundled with Core Investments.
- Strategic Engagement Model The firm's proprietary matchmaking platform connecting portfolio founders with senior buyers across payers, providers, and life sciences, contributing nearly $1B in direct revenue to Flare Capital's portfolio companies. Provided to portfolio companies as part of Core Investments.
Quantifiable outcome
- ~$1B in assets under management
- +11 more outcomes
Companies that use Flare Capital Partners
Customer profileNamed customers15 records
Segments4 records
Ideal customer profiles3 records
Flare Capital Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature3 records
Flare Capital Partners partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered flagship.
- Amazon Web Services (AWS)flagshipAI Advisory Council partnership: Jared Saul (Former Chief Medical Officer, Commercial Health & Life Sciences at AWS, External Advisor) sits on the Flare Capital AI Advisory Council, supporting cloud and AI infrastructure scaling for portfolio companies.
- AmgenflagshipAI Advisory Council partnership: Sean Bruich (Chief Technology Officer at Amgen) sits on the Flare Capital AI Advisory Council, providing life sciences AI deployment perspective.
- Banner HealthflagshipAI Advisory Council partnership: Kelly Ko (VP of Technology Ventures and Innovation at Banner Health) sits on the Flare Capital AI Advisory Council, with additional representation on the IAB. Banner Health also hosts Flare Scholars.
- GuideWell / Florida BlueflagshipAI Advisory Council partnership: Svetlana Bender, PhD (VP, AI and Behavioral Science at GuideWell & Florida Blue) sits on the Flare Capital AI Advisory Council, providing payer-side AI deployment perspective.
- CVS HealthflagshipIndustry Advisory Board partnership: Sreekanth Chaguturu, MD (EVP and Chief Medical Officer at CVS Health) represents CVS Health on Flare Capital's IAB. CVS Health is also a strategic investor via CVS Health Ventures, co-investing with Flare Capital in portfolio companies such as Oshi Health (Series C, Oct 2024) and Knownwell ($25M round, Oct 2025). Tilak Mandadi (EVP, Ventures, Chief Experience and Technology) also sits on the AI Advisory Council. CVS Health represents significant insured lives and revenue, contributing to the IAB's ~$1.2T revenue footprint.
- MicrosoftflagshipAI Advisory Council partnership: Peter Durlach (Former CVP, Chief Strategy Officer, Microsoft Health & Life Sciences) sits on the Flare Capital AI Advisory Council, providing Microsoft Azure / healthcare AI deployment perspective.
- FreseniusflagshipIndustry Advisory Board partnership: Thomas Brouillard (CFO Global Care Delivery at Fresenius) sits on the Flare Capital IAB, supporting care delivery and dialysis-focused portfolio opportunities.
- PfizerflagshipIndustry Advisory Board partnership: Aaron Foster (VP, Business Analytics and Insights at Pfizer) sits on the Flare Capital IAB. Pfizer contributes to the IAB's $1.2T aggregate revenue footprint and supports portfolio companies with life sciences commercial pathways.
- HumanaflagshipIndustry Advisory Board partnership: Chase Tacker (SVP, Corporate Development at Humana) sits on the Flare Capital IAB. Humana is also a key payer partner for Greater Good Health's value-based primary care clinics.
- MedStar HealthflagshipIndustry Advisory Board partnership: Susan K. Nelson (EVP and CFO at MedStar Health) sits on the Flare Capital IAB. MedStar Health ($7.7B) is also a strategic partner of Flare Capital portfolio company Suki. William Sheahan (Chief Innovation Officer & SVP) represents MedStar on the AI Advisory Council.
- Boston Children's HospitalflagshipIndustry Advisory Board partnership: Sandra L. Fenwick (CEO, Emeritus of Boston Children's Hospital) sits on the Flare Capital IAB, supporting pediatric and digital health portfolio companies.
- Cleveland ClinicflagshipIndustry Advisory Board partnership: Todd Schwarzinger sits on the Flare Capital IAB representing Cleveland Clinic, contributing clinical and operational validation pathways for portfolio companies.
- Advocate HealthflagshipIndustry Advisory Board partnership: Rasu B. Shrestha, MD, MBA (Enterprise EVP and Chief Innovation and Commercialization Officer at Advocate Health) sits on the Flare Capital IAB, supporting health system adoption of portfolio innovation.
- Centene CorporationflagshipIndustry Advisory Board partnership: Beau Garverick (SVP, Corporate Development and Strategy at Centene) sits on the Flare Capital IAB, providing managed care and Medicaid pathway validation for portfolio companies.
- Hartford HealthcareflagshipIndustry Advisory Board partnership: Barry Stein, MD (VP, Chief Clinical Innovation Officer and Chief Medical Informatics Officer at Hartford Healthcare) sits on the Flare Capital IAB, supporting clinical innovation adoption.
- UPMC EnterprisesflagshipIndustry Advisory Board partnership: Brenton Burns (EVP at UPMC Enterprises) sits on the Flare Capital IAB, unlocking payer-provider commercialization channels for portfolio companies.
- Allina HealthflagshipIndustry Advisory Board partnership: Lawrence Cho (Chief Strategy and Growth Officer at Allina Health) sits on the Flare Capital IAB.
- LabcorpflagshipIndustry Advisory Board partnership: Brian Caveney, MD, JD, MPH (Chief Medical and Scientific Officer at Labcorp) sits on the Flare Capital IAB.
- AdventHealthflagshipIndustry Advisory Board partnership: Jeffrey E. Graff, CFA (SVP/Treasury and Chief Corporate Development Officer at AdventHealth) sits on the Flare Capital IAB.
Scale indicators14 records
Recent moves6 records
Expansion highlights6 records
Flare Capital Partners competitors and assessment
Company assessmentDirect peers
- General Catalyst: Multi-stage venture firm with a dedicated Health Assurance platform and deep healthtech investing practice. Directly comparable as a healthtech-focused institutional investor with operator network and similar founder partnership model.
- Andreessen Horowitz (a16z Bio): Operates a dedicated bio/health fund ($1.5B+) investing in healthcare and life sciences companies from seed to growth. Direct peer in scale, stage range, and healthtech specialization with strong network-driven platform services.
- GV (Google Ventures): Alphabet's venture arm with substantial healthcare practice across consumer health, digital health, and biotech. Direct peer given multi-stage healthtech investing and similar thesis on rebuilding healthcare with software, data, and AI.
- Oak HC/FT: Pure-play healthtech and financial services venture firm investing from seed to growth. Co-invests with Flare Capital in portfolio companies like Oshi Health, making it a direct competitor for the same healthtech AI and care delivery deals.
- Define Ventures: Pure-play healthtech venture firm led by Lynne O'Keefe and Derek Streat. Co-invests with Flare Capital in deals like Layer Health, making it a direct peer in early-to-growth stage healthtech AI and digital health investing.
- Venrock: Early-stage venture firm with strong healthcare and technology practice dating back decades. Direct peer in early-stage healthtech investing with similar focus on healthcare transformation and founder partnership.
- ARCH Venture Partners: Premier early-stage venture firm focused on life sciences, biotech, and physical sciences including healthtech. Direct peer in deep-tech healthcare investing with similar focus on transformational healthcare companies.
Broad incumbents
- Khosla Ventures: Large multi-stage venture firm with significant healthtech and biotech practice across its portfolio. Broader incumbent that competes for healthtech deals but operates across many sectors beyond healthcare.
- Bessemer Venture Partners: Established multi-stage venture firm with dedicated healthcare practice. Co-investor with Flare Capital in portfolio companies like Oshi Health, representing a broader incumbent competing across multiple sectors.
- New Enterprise Associates (NEA): One of the largest venture firms with deep healthcare practice and significant AUM. Led Qualified Health's $125M Series B alongside Flare Capital, representing a broader incumbent with diversified stage and sector exposure.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Flare Capital Partners social profiles
Digital presenceFlare Capital Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Flare Capital Partners leadership team
Management profileNumber of profiles
Profiles18 records
Flare Capital Partners subsidiaries and ownership
Company hierarchySubsidiaries1 record
Flare Capital Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Flare Capital Partners M&A and investment
M&A and investmentM&A
Investments119 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Flare Capital Partners
What does Flare Capital Partners do?
Flare Capital Partners provides venture capital investment, network-driven portfolio acceleration, and talent-community engagement exclusively to U.S. healthcare technology founders. Its primary offering is direct equity investment of $5 million to $30 million per company across Seed to Series B rounds with 10%–20% target ownership, complemented by a ~$100K pre-seed vehicle (Flare Scholar Ventures), a 35-member Industry Advisory Board opening enterprise buyer relationships, a 14-member AI Advisory Council supporting AI deployments, and a 509-member Flare Scholars talent community that sources both deals and operating talent.
Is Flare Capital Partners a public or private company?
Flare Capital Partners is a private company. It is classified as management employee owned and is currently operating.
When was Flare Capital Partners founded?
Flare Capital Partners was founded in 2011. It employs 11 to 50 people.
Where is Flare Capital Partners based?
Flare Capital Partners is headquartered in Boston, United States, in the North America region.
How does Flare Capital Partners make money?
Two revenue lines are on record. Fund Management (implied) is the primary driver. The others are portfolio Exits / Carried Interest (implied).
Who are Flare Capital Partners's main competitors?
Direct peers on record are General Catalyst, Andreessen Horowitz (a16z Bio), GV (Google Ventures), Oak HC/FT, Define Ventures, Venrock and ARCH Venture Partners. Broad incumbents are Khosla Ventures, Bessemer Venture Partners and New Enterprise Associates (NEA).
Does Flare Capital Partners have an API?
No public API is recorded for Flare Capital Partners.
What industry is Flare Capital Partners in?
Flare Capital Partners's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B), with a secondary code of FSANAAAC, Late-Stage Venture Capital (Series C+). Its NAICS code is 523150 and its SIC code is 6211.